Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CRIMSON URGENT CARE, LLC

NPI: 1831205228 · TUSCALOOSA, AL 35404 · Urgent Care Clinic/Center · NPI assigned 08/21/2006

$1.45M
Total Medicaid Paid
71,603
Total Claims
56,573
Beneficiaries
41
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialPERAMSETTY, SASANK (MEDICAL DIRECTOR)
NPI Enumeration Date08/21/2006

Related Entities

Other providers sharing the same authorized official: PERAMSETTY, SASANK

ProviderCityStateTotal Paid
CRIMSON CARE LLC TUSCALOOSA AL $1.50M
FIRST KIDS TUSCALOOSA AL $1.35M
FIRST CARE LLC TUSCALOOSA AL $812K
ALABAMA FAMILY MEDICAL CENTER, LLC TUSCALOOSA AL $168K
CRIMSON CARE NORTH NORTHPORT AL $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 110 $816.13
2019 131 $667.20
2020 8,338 $191K
2021 15,665 $317K
2022 18,044 $338K
2023 19,054 $456K
2024 10,261 $147K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 7,955 6,677 $355K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5,057 4,193 $316K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 2,863 2,619 $206K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 5,784 5,230 $99K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 11,887 5,116 $79K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 634 574 $69K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 2,455 2,053 $58K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward 1,325 1,141 $49K
87428 1,040 937 $44K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 5,094 4,300 $42K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 2,355 1,811 $36K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 3,194 2,804 $29K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 533 454 $18K
71046 Radiologic examination, chest; 2 views 1,196 1,033 $18K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 5,372 4,730 $13K
87807 712 611 $5K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction 684 586 $4K
J0696 Injection, ceftriaxone sodium, per 250 mg 1,953 1,679 $3K
81002 1,263 1,115 $2K
M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring 16 13 $2K
J1885 Injection, ketorolac tromethamine, per 15 mg 997 868 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg 2,750 2,370 $985.11
81025 320 285 $599.79
81003 74 51 $114.00
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 84 77 $110.93
S0077 Injection, clindamycin phosphate, 300 mg 34 31 $43.12
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram 630 540 $0.52
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg 681 585 $0.14
3079F 78 69 $0.00
2010F 396 349 $0.00
3074F 353 303 $0.00
1170F 667 568 $0.00
3008F 539 462 $0.00
3080F 25 24 $0.00
2001F 531 469 $0.00
1160F 538 474 $0.00
A7003 Administration set, with small volume nonfiltered pneumatic nebulizer, disposable 349 330 $0.00
1159F 539 475 $0.00
3078F 244 209 $0.00
1494F 390 346 $0.00
3077F 12 12 $0.00